BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 9384668)

  • 1. Preemptive Interferon-α Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies.
    Shen MZ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Zhao XS; Qin YZ; Chang YJ; Liu KY; Huang XJ; Mo XD
    Front Immunol; 2022; 13():757002. PubMed ID: 35154096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type 1 interferon to prevent leukemia relapse after allogeneic transplantation.
    Magenau JM; Peltier D; Riwes M; Pawarode A; Parkin B; Braun T; Anand S; Ghosh M; Maciejewski J; Yanik G; Choi SW; Talpaz M; Reddy P
    Blood Adv; 2021 Dec; 5(23):5047-5056. PubMed ID: 34607341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
    Glass B; Majolino I; Dreger P; Scimè R; Santoro A; Vasta S; Suttorp M; Haferlach T; Schmitz N
    Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
    Zuffa E; Bandini G; Bonini A; Santucci MA; Martinelli G; Rosti G; Testoni N; Zaccaria A; Tura S
    Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
    Massumoto C; Benyunes MC; Sale G; Beauchamp M; York A; Thompson JA; Buckner CD; Fefer A
    Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation.
    Giralt S; O'Brien S; Talpaz M; Van Besien K; Chan KW; Rondón G; Andersson B; Mehra R; Khouri I; Estey E
    Cytokines Mol Ther; 1995 Jun; 1(2):115-22. PubMed ID: 9384668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Status of recombinant cytokines in treatment of leukemic diseases].
    Geissler K
    Wien Med Wochenschr; 1991; 141(9-10):217-20. PubMed ID: 1949848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on therapeutic options for chronic myelogenous leukemia.
    Talpaz M; Kantarjian H; Kurzrock R; Gutterman JU
    Semin Hematol; 1990 Jul; 27(3 Suppl 4):31-6. PubMed ID: 2197731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon alfa has become a standard in the treatment of chronic myelogenous leukemia.
    Freund M; Huber C
    Semin Hematol; 1993 Jul; 30(3 Suppl 3):1-5. PubMed ID: 8235694
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of interleukin-2 in human hematological malignancies.
    Toren A; Ackerstein A; Slavin S; Nagler A
    Med Oncol; 1995 Sep; 12(3):177-86. PubMed ID: 8852400
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.